GenOway Overview
- Year Founded
-
1999
- Status
-
Public
- Employees
-
163
- Stock Symbol
-
ALGEN
- Investments
-
6
- Share Price
-
$2.09
- (As of Friday Closing)
GenOway General Information
Description
Genoway SA specializes in genetic designs to serve genetically modified (GM) mice, rat and cell lines for the biopharmaceutical industries and research industries.
Contact Information
Website
www.genoway.comCorporate Office
- 31 Rue Saint Jean de Dieu
- 69007 Lyon
- France
Corporate Office
- 31 Rue Saint Jean de Dieu
- 69007 Lyon
- France
GenOway Stock Performance
As of 20-Nov-2026, GenOway’s stock price is $2.09. Its current market cap is $25.8M with 12.3M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.09 | $2.14 | $1.97 - $3.39 | $25.8M | 12.3M | 8.96K | -$0.17 |
GenOway Financials Summary
As of 30-Jun-2026, GenOway has a trailing 12-month revenue of $23.1M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 41,064 | 53,025 | 37,312 | 47,520 |
| Revenue | 23,067 | 23,639 | 23,870 | 21,692 |
| EBITDA | 2,655 | 5,570 | 5,543 | 6,837 |
| Net Income | (2,446) | 1,047 | 1,981 | 1,696 |
| Total Assets | 52,386 | 53,274 | 33,090 | 35,199 |
| Total Debt | 17,380 | 16,175 | 5,802 | 7,996 |
GenOway Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
GenOway Comparisons
Industry
Financing
Details
GenOway Competitors (32)
One of GenOway’s 32 competitors is Celprogen, a Private Debt Financed company based in Torrance, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Celprogen | Private Debt Financed | Torrance, CA | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA | ||||
| Premas Biotech | Venture Capital-Backed | Gurugram, India | ||||
| GemPharmatech | Formerly VC-backed | Nanjing, China | ||||
| Lake Immunogenics | Private Debt Financed | Ontario, NY |
GenOway Patents
GenOway Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-1814998-A2 | Animal models comprising at least one conditional ko and one conditional ki | Active | 08-Nov-2004 | ||
| EP-1814998-B1 | Animal models comprising at least one conditional ko and one conditional ki | Inactive | 08-Nov-2004 | ||
| US-20090062477-A1 | Animal models comprising at least one conditional ko and one conditional ki | Inactive | 08-Nov-2004 | ||
| WO-2006048466-A2 | Animal models comprising at least one conditional ko and one conditional ki | Inactive | 08-Nov-2004 | ||
| WO-2006048466-A3 | Animal models comprising at least one conditional ko and one conditional ki | Inactive | 08-Nov-2004 | C12N15/8509 |
GenOway Signals
GenOway Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
GenOway Investments & Acquisitions (6)
GenOway’s most recent deal was a Corporate Asset Purchase with OMICS Platform (Data Science and AI Assets) for . The deal was made on 16-Dec-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| OMICS Platform (Data Science and AI Assets) | 16-Dec-2025 | Corporate Asset Purchase | Buildings and Property | ||
| Joint Venture (Chinese Partners / GenOway) | 17-Oct-2023 | Joint Venture | Distributors (Healthcare) | ||
| Merck (Worldwide Rights on Foundational CRISPR/Cas9 Portfolio) | 01-Dec-2018 | Corporate Asset Purchase | Buildings and Property | ||
| Axenis | 06-Sep-2018 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology | ||
| Bluebird Bio (RMCE Technology Global License) | 12-Jul-2011 | Merger/Acquisition | Biotechnology |
GenOway ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
GenOway FAQs
-
When was GenOway founded?
GenOway was founded in 1999.
-
Where is GenOway headquartered?
GenOway is headquartered in Lyon, France.
-
What is the size of GenOway?
GenOway has 163 total employees.
-
What industry is GenOway in?
GenOway’s primary industry is Biotechnology.
-
Is GenOway a private or public company?
GenOway is a Public company.
-
What is GenOway’s stock symbol?
The ticker symbol for GenOway is ALGEN.
-
What is the current stock price of GenOway?
As of 20-Nov-2026 the stock price of GenOway is $2.09.
-
What is the current market cap of GenOway?
The current market capitalization of GenOway is $25.8M.
-
What is GenOway’s current revenue?
The trailing twelve month revenue for GenOway is $23.1M.
-
Who are GenOway’s competitors?
Celprogen, Genetix Biotherapeutics, Premas Biotech, GemPharmatech, and Lake Immunogenics are some of the 32 competitors of GenOway.
-
What is GenOway’s annual earnings per share (EPS)?
GenOway’s EPS for 12 months was -$0.17.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process